Latest news with #Terumo
Nikkei Asia
23-05-2025
- Business
- Nikkei Asia
Japanese medical device makers stand up to Trump tariff pressure
TOKYO -- Japanese medical device manufacturers are showing resilience to U.S. tariff threats thanks to their specialized manufacturing expertise, focus on niche markets and pricing power. Leading manufacturers such as Terumo and Olympus, both based in Tokyo, are expected to pass on at least some of the tariff costs to U.S. customers.
Yahoo
16-05-2025
- Business
- Yahoo
Terumo Corp (TRUMF) Full Year 2025 Earnings Call Highlights: Record Sales and Strategic Growth ...
Release Date: May 14, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Terumo Corp (TRUMF) achieved record high sales revenues surpassing JPY1 trillion for the first time, with a 12% growth over the previous year. Operating profit reached a record high for the fourth consecutive year, despite a one-time expense, due to strong revenue growth. Free cash flow increased significantly, exceeding JPY100 billion for the first time, driven by expanded operating cash flow. The cardiovascular company segment showed strong global sales revenue growth, particularly in the US, with an 8% increase on a local currency basis. The company expects a 32% increase in operating profit for fiscal 2025, driven by business expansion and the absence of previous one-time expenses. General and administrative expenses increased due to additional provisions for bonuses and one-time litigation expenses. The company faced negative gross margin effects due to the loss and writedown of products in preparation for new product expansion. Price declines in China due to value-based purchasing impacted revenue, although partially offset by price increases elsewhere. The impact of US reciprocal tariffs remains uncertain, with a potential maximum impact of approximately JPY17 billion. Challenges in the external environment, such as inflation and currency fluctuations, have negatively affected certain business segments. Warning! GuruFocus has detected 2 Warning Signs with TRUMF. Q: Can you elaborate on the factors driving the record high sales revenue and operating profit for fiscal year 2024? A: Jin Hagimoto, Chief Financial Officer, explained that sales revenues surpassed JPY1 trillion for the first time, with a 12% growth over the previous year. This was driven by global demand, particularly in the US, and a weaker JPY. Operating profit also reached a record high due to this growth, despite a one-time expense of 24.2 billion yen. Net income and free cash flow also hit record highs. Q: What are the expectations for fiscal year 2025 in terms of revenue and operating profit growth? A: CFO Jin Hagimoto stated that for fiscal year 2025, Terumo expects a 7% revenue growth on a local currency basis and a 32% increase in operating profit. This growth is anticipated due to business expansion and the absence of one-time expenses from the previous year. Q: How did regional performance contribute to the company's overall growth? A: CFO Jin Hagimoto highlighted that all regions showed steady progress, with the Americas and Europe posting double-digit growth. In China, the TIS segment rebounded from price declines due to value-based purchasing with increased volumes. Q: Can you discuss the impact of the US reciprocal tariffs on Terumo's financial outlook? A: CFO Jin Hagimoto mentioned that the maximum estimated impact of the US reciprocal tariffs for the current fiscal year is approximately JPY17 billion. This estimate assumes most US sales, other than those produced in the Americas, are imported from Japan. The economic impact is expected from the second quarter onwards, but it has not been factored into the fiscal 2025 guidance. Q: What strategic measures are being taken under the GS 26 growth strategy? A: CFO Jin Hagimoto outlined that the GS 26 strategy focuses on expanding therapeutic businesses, promoting radial procedures, and enhancing preoperative solutions with smart pumps. Additionally, Terumo is accelerating global expansion in blood and cell technology and expanding its software and service businesses for competitive advantage. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Recorder
14-05-2025
- Business
- Business Recorder
Japan's Nikkei reverses gains on sell-off to book profits
TOKYO: Japan's Nikkei share average reversed course to trade lower on Wednesday as investors sold stocks to book profits, while the broader Topix is set to snap its longest winning streak in nearly 16 years. The Nikkei fell 0.81% at 37,874.59 by the midday break. The broader Topix fell 1.21% to 2,738.59, on course to snap a 13-day winning streak, its longest since August 2009. The Nikkei hit a three-month high on Tuesday, buoyed by hopes for more deals between major economies after the US and China agreed to temporarily slash harsh reciprocal tariffs. 'The market had set the 38,000 as a target after the Nikkei tanked last month, following the announcement of (US President Donald) Trump's tariffs,' said Hiroyuki Ueno, chief strategist at Sumitomo Mitsui Trust Asset Management. Japan's Nikkei rises on US-China trade deal hopes 'The index hit that target earlier than expected, and that prompted investors to sell stocks to book profits today.' Uniqlo-brand owner Fast Retailing fell 1.19% to drag down the Nikkei the most. Healthcare equipment maker Terumo fell 3.3%. Yaskawa Electric fell 4.44% after the robot maker was excluded from MSCI's standard index in its regular reshuffle. Heavy machinery maker IHI rose 2.03% as it was included in the index. Of more than 1,600 stocks trading on the Tokyo Stock Exchange's prime market, 15% rose and 82% fell, with 1% trading flat.
Yomiuri Shimbun
07-05-2025
- Business
- Yomiuri Shimbun
Japan's Nikkei Heavy as US Tariff Woes Counter China Optimism
Yomiuri Shimbun file photo The Tokyo Stock Exchange TOKYO, May 7 (Reuters) – Japan's Nikkei share average ticked lower on Wednesday, threatening to end a seven-session winning streak, as pharmaceutical shares led losses after U.S. President Donald Trump said he would reveal tariffs on drugs over the next two weeks. Automaker stocks slumped as Japanese investors returned from a four-day weekend to an overall stronger yen, cutting the value of overseas revenues. Sony Group, which runs a movie studio, sank following Trump's announcement of a 100% levy on foreign-made films. Tariff worries overshadowed any improvement in market sentiment kindled by news that U.S. Treasury Secretary Scott Bessent and chief trade negotiator Jamieson Greer will meet China's economic tsar, He Lifeng, in Switzerland this weekend for talks. Investors were also reluctant to push the Nikkei above Friday's five-week peak before the conclusion of the Federal Reserve's two-day policy meeting later in the day. With so many issues regarding tariffs still unresolved, investors are not in a position to chase the market higher, said Nomura strategist Fumika Shimizu. 'The seven-day rally may be acting as a weight on the market.' The Nikkei ended the morning session down 0.05% after fluctuating in a very narrow range on either side of Friday's closing level. The biggest drags on the index included Sony and drugmaker Terumo, along with heavily weighted Uniqlo operator Fast Retailing. Sony lost 3.4%, Terumo declined 2.3% and Fast Retailing shed 1.5%. Overall, though, the Nikkei's performance was fairly balanced, with 120 of its 225 components rising, 101 falling and four flat. The broader Topix, by contrast, rose 0.4%. The Nikkei's biggest decliner in percentage terms was Sumitomo Pharma, which slumped 6.7%. Peers Otsuka Holdings and Eisai rounded out the bottom three, dropping 4.9% and 4.4% respectively. Mitsubishi Motors was the worst-faring automaker, sliding 2.7%. Toyota lost 2.1% ahead of its earnings release on Thursday. Trading houses were a bright spot after Berkshire Hathaway affirmed its commitment to investments in those businesses even as Warren Buffett stepped aside as CEO. Marubeni jumped 5.8% and Mitsubishi Corp advanced 3.4%.
Business Recorder
07-05-2025
- Business
- Business Recorder
Japan's Nikkei heavy as US tariff woes counter China optimism
TOKYO: Japan's Nikkei share average ticked lower on Wednesday, threatening to end a seven-session winning streak, as pharmaceutical shares led losses after US President Donald Trump said he would reveal tariffs on drugs over the next two weeks. Automaker stocks slumped as Japanese investors returned from a four-day weekend to an overall stronger yen, cutting the value of overseas revenues. Sony Group, which runs a movie studio, sank following Trump's announcement of a 100% levy on foreign-made films. Tariff worries overshadowed any improvement in market sentiment kindled by news that US Treasury Secretary Scott Bessent and chief trade negotiator Jamieson Greer will meet China's economic tsar, He Lifeng, in Switzerland this weekend for talks. Investors were also reluctant to push the Nikkei above Friday's five-week peak before the conclusion of the Federal Reserve's two-day policy meeting later in the day. With so many issues regarding tariffs still unresolved, investors are not in a position to chase the market higher, said Nomura strategist Fumika Shimizu. 'The seven-day rally may be acting as a weight on the market.' The Nikkei ended the morning session down 0.05% after fluctuating in a very narrow range on either side of Friday's closing level. The biggest drags on the index included Sony and drugmaker Terumo, along with heavily weighted Uniqlo operator Fast Retailing. Japan's Nikkei closes at three-month low as tech shares drag Sony lost 3.4%, Terumo declined 2.3% and Fast Retailing shed 1.5%. Overall, though, the Nikkei's performance was fairly balanced, with 120 of its 225 components rising, 101 falling and four flat. The broader Topix, by contrast, rose 0.4%. The Nikkei's biggest decliner in percentage terms was Sumitomo Pharma, which slumped 6.7%. Peers Otsuka Holdings and Eisai rounded out the bottom three, dropping 4.9% and 4.4% respectively. Mitsubishi Motors was the worst-faring automaker, sliding 2.7%. Toyota lost 2.1% ahead of its earnings release on Thursday. Trading houses were a bright spot after Berkshire Hathaway affirmed its commitment to investments in those businesses even as Warren Buffett stepped aside as CEO. Marubeni jumped 5.8% and Mitsubishi Corp advanced 3.4%.
